Results 1 - 10 of 15

< 1 2 >

• [DOI: 10.1016/j.ejmech.2007.06.006]
  
• Beyond Trastuzumab: Second-Generation Targeted Therapies for HER-2-positive Breast Cancer, Drugs for HER-2-positive Breast Cancer

  [DOI: 10.1007/978-3-0346-0094-1_6]
  
• Multitarget Control of Drug Impact: A Therapeutic Imperative in Cancer Systems Biology, Biomolecular Interfaces

  [DOI: 10.1007/978-3-319-16850-0_13]
  
• Epistructure-Based Design of Drugs with Controlled Promiscuity, Physics at the Biomolecular Interface

  [DOI: 10.1007/978-3-319-30852-4_13]
  
• Fulfilling a Therapeutic Imperative in Cancer Treatment: Control of Multi-target Drug Impact, Transformative Concepts for Drug Design: Target Wrapping

  [DOI: 10.1007/978-3-642-11792-3_10]
  
• Putting the Brakes on Cancer, Pharmaceutical Innovation

  [DOI: 10.1007/BF03265453]
  
• Molecular target-based cancer therapy: tyrosine kinase inhibitors, International Journal of Clinical Oncology

  [DOI: 10.1007/s10147-003-0320-1]
  
• The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells, Breast Cancer Research and Treatment

  [DOI: 10.1007/s10549-010-1232-1]
  
• An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents, Clinical and Translational Oncology

  [DOI: 10.1007/s12094-012-0964-2]
  
• Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations, Pathology & Oncology Research

  [DOI: 10.1007/s12253-015-9916-9]